Wanjia (HKG:0401) expects a loss of around HK$5.8 million for the year ended March 31, down 86% from HK$40.3 million a year prior, a Thursday Hong Kong bourse filing said.
The pharmaceutical distribution company attributed the loss mainly to refunds of certain items related to hemodialysis treatment requested by a county medical security bureau in China from the firm's hemodialysis treatment centers.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。